CA2835232C - A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof - Google Patents

A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof Download PDF

Info

Publication number
CA2835232C
CA2835232C CA2835232A CA2835232A CA2835232C CA 2835232 C CA2835232 C CA 2835232C CA 2835232 A CA2835232 A CA 2835232A CA 2835232 A CA2835232 A CA 2835232A CA 2835232 C CA2835232 C CA 2835232C
Authority
CA
Canada
Prior art keywords
tomoxiprole
complex
cyclodextrin
beta
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2835232A
Other languages
English (en)
French (fr)
Other versions
CA2835232A1 (en
Inventor
Alberto Milanese
Marino Nebuloni
Lucia Carrano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Cariplo
Fondazione Istituto Insubrico di Ricerca per la Vita
Original Assignee
Fondazione Cariplo
Fondazione Istituto Insubrico di Ricerca per la Vita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Cariplo, Fondazione Istituto Insubrico di Ricerca per la Vita filed Critical Fondazione Cariplo
Publication of CA2835232A1 publication Critical patent/CA2835232A1/en
Application granted granted Critical
Publication of CA2835232C publication Critical patent/CA2835232C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2835232A 2011-07-01 2012-06-14 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof Expired - Fee Related CA2835232C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20111235 2011-07-01
ITMI2011A001235 2011-07-01
PCT/EP2012/061261 WO2013004462A1 (en) 2011-07-01 2012-06-14 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof

Publications (2)

Publication Number Publication Date
CA2835232A1 CA2835232A1 (en) 2013-01-10
CA2835232C true CA2835232C (en) 2017-02-14

Family

ID=44533012

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835232A Expired - Fee Related CA2835232C (en) 2011-07-01 2012-06-14 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof

Country Status (6)

Country Link
US (1) US8791269B2 (enExample)
EP (1) EP2726106B1 (enExample)
JP (1) JP2014518228A (enExample)
CA (1) CA2835232C (enExample)
ES (1) ES2547920T3 (enExample)
WO (1) WO2013004462A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334494A (zh) 2018-06-29 2021-02-05 罗盖特公司 新颖的羟丙基-β-环糊精及其生产方法
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012866B1 (en) 1978-12-21 1983-01-19 Gruppo Lepetit S.P.A. New 3h-naphtho(1,2-d)imidazoles, processes for preparing them, compounds for use as antiinflammatory and antimicrobial agents and compositions for that use containing them
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
ATE359827T1 (de) 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물

Also Published As

Publication number Publication date
ES2547920T3 (es) 2015-10-09
CA2835232A1 (en) 2013-01-10
US20140128343A1 (en) 2014-05-08
JP2014518228A (ja) 2014-07-28
WO2013004462A1 (en) 2013-01-10
US8791269B2 (en) 2014-07-29
EP2726106A1 (en) 2014-05-07
EP2726106B1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
JP6025861B2 (ja) カバジタキセルの結晶形およびこれを調製するための方法
CN101959846B (zh) O-去甲基-文拉法辛盐
CN102875634B (zh) 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN104356038B (zh) 维生素d2与d3的共晶及其制备方法和用途
US8791269B2 (en) Complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
CA2489708A1 (en) A process for the preparation of piroxicam: .beta.-cyclodextrin inclusion compounds
CN103951725A (zh) 17β雌二醇的哌嗪共结晶及其制备方法和应用
JP6908657B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN113197865B (zh) 醋酸阿比特龙与反式乌头酸的共晶、其制备方法、药物组合物及其应用
JPWO2002083633A1 (ja) トシル酸スプラタスト結晶
KR102544543B1 (ko) L,d-엘도스테인의 개별적 공결정화물
WO2018078383A1 (en) Pharmaceutical composition comprising amorphous selexipag
CN107540589A (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
Nagasamy Venkatesh et al. Dissolution enhancement of diacerein using water soluble carrier by solid dispersion technology
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
JP6887195B1 (ja) 新規有機ゲルマニウム化合物
EP1264821A1 (en) Novel crystal of stilbene derivative and process for producing the same
CN112999219B (zh) 含有穿心莲内酯的共无定形物及其制备方法和药物组合物
CA3191776A1 (en) Salts of fenfluramine
KR20110095545A (ko) (ｓ)-리바스티그민 오로트산염 및 이를 포함하는 약제학적 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150728

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831